Key result
Baseline troponin ≥15 ng/L linked to ~190% greater mortality risk in acute AF or flutter.
Why the study?
Current evidence does not support using troponin to differentiate uncomplicated tachyarrhythmia from significant CAD, prompting assessment of its utility in acute AF/AFL.
Does elevated troponin predict significant coronary artery disease and mortality in patients with acute atrial fibrillation/flutter in the emergency department?
Cohort (n=3,425)
No
Does elevated troponin predict significant coronary artery disease and mortality in patients with acute atrial fibrillation/flutter in the emergency department?
Elevated baseline and dynamic troponin levels in ED patients with acute AF/AFL are strongly associated with significant CAD and increased all-cause mortality, suggesting the need for tailored diagnostic thresholds.
Answers are grounded in this paper and cite their sources.
May aid mortality risk assessment in acute AF/AFL; leaves open whether troponin-guided CAD evaluation improves outcomes.
Troponin is a crucial biomarker in the emergency department (ED). Current evidence does not support differentiation between an uncomplicated tachyarrhythmia and significant coronary artery disease (CAD). The aim of the present study was to assess the use of troponins to predict CAD and mortality in patients with acute atrial fibrillation/flutter (AF/AFL). This cohort study included 3,425 consecutive episodes with AF/AFL treated at the ED of the Medical University of Vienna between 2012 and 2024. Coronary angiography was performed in 251 cases. Patients were grouped according to the troponin levels (ng/L): 0-4; 5-14; 15-28; 29-51 and ≥ 52. Outcomes were significant CAD and mortality. Of all cases (n = 3,425), coronary angiography was performed within 30 days in 251 (7%); 115 (46%) had significant CAD. The rate increased with rising troponin levels: baseline troponin, ng/L, %: 5-14: 32, 15-28: 38, 29-51: 47, ≥ 52: 57; p = 0.028; serial troponin, ng/L, %: 5-14: 15, 15-28: 19; 29-51: 54; ≥ 52: 66; p < 0.001. Sensitivity for significant CAD at 5 ng/L was 99%; specificity at ≥ 52 ng/L was 77% and increased to > 92% at ≥ 92 ng/L. 713 patients (21%) died in an observation time of 13,771 years. A troponin value ≥ 15 ng/L was significantly associated with all-cause mortality. Prevalence of significant CAD increases with rising and dynamic troponin levels. Troponin thresholds for further diagnostics or interventions may be different in AF/AFL than in the general population. Elevated troponin levels at baseline and in subsequent measurements as well as significant changes are associated with an increased all-cause mortality.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2025) conducted a cohort in Acute atrial fibrillation/flutter (n=3,425). Elevated baseline troponin (≥ 15 ng/L) vs. Lower baseline troponin was evaluated on All-cause mortality (HR 2.90, 95% CI 2.32-3.62, p=<0.001). Baseline troponin levels ≥ 15 ng/L were associated with an increased risk of all-cause mortality in patients treated for acute atrial fibrillation or flutter.
Synapse has enriched 10 related papers. Consider them for comparative context: